Perry Nisen Ph.D Overview
- Firm
- Sofinnova Invest...
- Primary Position
-
Executive Partne...
- Primary Industry
-
Healthcare
- Active Board Seats
-
3
- Med. Deal Size
-
- Med. Valuation
-
Perry Nisen Ph.D General Information
Biography
Dr. Perry Nisen serves as Executive Partner, Private Equity at Sofinnova Investments. Dr. Nisen serves as Chief Executive Officer & Board Member at Quanta Therapeutics. He serves as Board Member at XyloCor Therapeutics. He became CEO of Quanta Therapeutics in June 2021 after having served as the founding Executive Chairman of the company during formation in his role as Executive Partner at Sofinnova Investments beginning in 2018. He is a physician scientist with extensive experience in drug discovery and development with particular interest in oncology. He is the former CEO of the Sanford Burnham Prebys Medical Discovery Institute (SBP). As CEO, he was responsible for all aspects of the organization including strategy, operations and performance. Prior to SBP, he held multiple senior leadership positions during his tenure at GlaxoSmithKline (GSK) including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head. Responsibilities at GSK included all aspects of drug discovery, clinical development, risk/benefit and operations. Before GSK, he was the Divisional Vice President, Cancer Research then Oncology Clinical Development at Abbott Laboratories. Prior to industry he was the Lowe Foundation Professor at the University of Texas Southwestern Medical Center. He holds a BS from Stanford University, and MD/PhD from the Albert Einstein College of Medicine. He is also an independent Director of TEVA Pharmaceuticals, and chair of their science and technology committee.
Contact Information
Address
- 3000 Sand Hill Road
- Building 3-Suite 150
- Menlo Park, CA 94025
- United States
Perry Nisen Ph.D Positions (3)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Quanta Therapeutics | Company | Chief Executive Officer & Board Member | South San Francisco, CA | Drug Discovery | |
Sanford-Burnham Medical Research Institute | Chief Executive Officer | La Jolla, CA | |||
Sofinnova Investments | Investor | Executive Partner, Private Equity | Menlo Park, CA | Venture Capital |
Perry Nisen Ph.D Board Seats (3)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Quanta Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | South San Francisco, CA | |
Teva Pharmaceutical Industries | Pharmaceuticals | Publicly Held | Corporation | Tel Aviv, Israel | |
XyloCor Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Wayne, PA |
Perry Nisen Ph.D Lead Partner on Deals (1)
Perry Nisen Ph.D has been the lead partner on 1 deal. Their latest deal was with XyloCor Therapeutics, a drug discovery company. The deal was made for on 20-Jan-2021.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
XyloCor Therapeutics | 20-Jan-2021 | Later Stage VC (Series A1) | Completed | Drug Discovery | Wayne, PA |
Perry Nisen Ph.D Network (69)
Board Members (51)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Arjun Goyal MD | Quanta Therapeutics | Vida Ventures (Boston) | South San Francisco, CA | |
Amir Elstein | Teva Pharmaceutical Industries | Self | Tel Aviv, Israel | |
Teva Pharmaceutical Industries | Gamida Cell | Tel Aviv, Israel | ||
Teva Pharmaceutical Industries | Self | Tel Aviv, Israel | ||
Teva Pharmaceutical Industries | Self | Tel Aviv, Israel |
Portfolio Executives (8)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Eric Duckers Ph.D | XyloCor Therapeutics | Chief Medical Officer | 20-Jan-2021 | Wayne, PA |
Howard Dittrich MD | XyloCor Therapeutics | Senior Vice President Research & Development | 20-Jan-2021 | Wayne, PA |
XyloCor Therapeutics | Chief Technology Officer, Head of Technical Operations and Head of Chemistry, Manufacturing and Controls | 20-Jan-2021 | Wayne, PA | |
XyloCor Therapeutics | Chief Financial Officer | 20-Jan-2021 | Wayne, PA | |
XyloCor Therapeutics | Vice President of Finance | 20-Jan-2021 | Wayne, PA |
Fund Team Members (10)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Anand Mehra MD | Sofinnova Investments | Sofinnova Venture Partners X | Menlo Park, CA |
Jason Pitts Ph.D | Sofinnova Investments | Sofinnova Venture Partners X | Menlo Park, CA |
Sofinnova Investments | Menlo Park, CA | ||
Sofinnova Investments | Menlo Park, CA | ||
Sofinnova Investments | Menlo Park, CA |
Perry Nisen Ph.D Affiliated Funds (1)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Sofinnova Venture Partners X | Sofinnova Investments | Venture - General | Closed | 2016 |
Perry Nisen Ph.D FAQs
-
Who is Perry Nisen Ph.D?
Dr. Perry Nisen serves as Executive Partner, Private Equity at Sofinnova Investments.
-
How much does Perry Nisen Ph.D typically invest?
Perry Nisen Ph.D's median deal size is
. -
What is Perry Nisen Ph.D’s main position?
Perry Nisen Ph.D’s primary position is Executive Partner, Private Equity.
-
What are the contact details for Perry Nisen Ph.D?
Perry Nisen Ph.D’s email address is pe
and his phone number is +1 (650) . -
How many active board seats does Perry Nisen Ph.D hold?
Perry Nisen Ph.D holds 3 board seats including Quanta Therapeutics, Teva Pharmaceutical Industries, and XyloCor Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »